Topical and systemic retinoid therapy for cutaneous T-cell lymphoma

Hematology/Oncology Clinics of North America

Volumn 17, Issue 6, 2003, Pages 1405-1419

  Kempf, Werner ^a   Kettelhack, Natascha ^a   Duvic, Madeleine ^b   Burg, Günter ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 [2 (5,6,7,8 TETRAHYDRO 5,5,8,8 TETRAMETHYL 2 NAPHTHYL) 1 PROPENYL]BENZOIC ACID ETHYL ESTER; ALITRETINOIN; ANTILIPEMIC AGENT; ANTINEOPLASTIC AGENT; ATORVASTATIN; BEXAROTENE; BLEOMYCIN; CALCITRIOL; CHLORMETHINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; ETRETIN; ETRETINATE; FENOFIBRATE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INTERFERON; ISOTRETINOIN; PREDNISOLONE; RETINOID; RETINOID X RECEPTOR; STEROID; TAZAROTENE; TUMOR NECROSIS FACTOR ALPHA; VITAMIN D DERIVATIVE;

ADVANCED CANCER; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BONE PAIN; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CLINICAL TRIAL; CUTANEOUS T CELL LYMPHOMA; DERMATITIS; DISSEMINATED SARCOID LIKE GRANULOMA; DRUG RESPONSE; DRY SKIN; EARLY CANCER; ELECTRON BEAM; GENETIC POLYMORPHISM; HAIR LOSS; HEADACHE; HISTOLOGY; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; HYPOTHYROIDISM; LEUKOPENIA; LIVER DYSFUNCTION; LIVER ENZYME ELEVATION; LYMPHOCYTIC INFILTRATION; MONOTHERAPY; MUCOUS MEMBRANE DRYNESS; MULTIMODALITY CANCER THERAPY; MYALGIA; MYCOSIS FUNGOIDES; OSTEOARTHROPATHY; PANCREATITIS; PHARMACOGENOMICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; PUVA; QUALITY OF LIFE; RETINOID DERMATITIS; REVIEW; SARCOIDOSIS; SEZARY SYNDROME; SKIN DISEASE; SKIN IRRITATION; TOTAL BODY SKIN ELECTRON BEAM; VITAMIN METABOLISM; XEROSIS;

EID: 0345735908     PISSN: 08898588     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8588(03)00107-2     Document Type: Review

References (86)

1. Burg G, Braun-Falco O. Cutaneous lymphomas, pseudolymphomas, and related disorders. Berlin: Springer; 1983.
2. Burg G, Kempf W, Haeffner AC, et al. Cutaneous lymphomas. Curr Probl Dermatol 1997;9(5): 137-204.
3. Weinstock MA, Gardstein B. Twenty-year trends in the reported incidence of mycosis fungoides and associated mortality. Am J Public Health 1999;89(8):1240-4.
4. Burg G, Dummer R, Haeffner A, et al. From inflammation to neoplasia: mycosis fungoides evolves from reactive inflammatory conditions (lymphoid infiltrates) transforming into neoplastic plaques and tumors [comment]. Arch Dermatol 2001;137(7):949-52.
5. Dummer R, Michie SA, Kell D, et al. Expression of bcl-2 protein and Ki-67 nuclear proliferation antigen in benign and malignant cutaneous T-cell infiltrates. J Cutan Pathol 1995;22(1):11-7.
6. Kim YH, Hoppe RT. Mycosis fungoides and the Sezary syndrome. Semin Oncol 1999;26(3): 276-89.
7. Burg G, Dummer R. Historical perspective on the use of retinoids in cutaneous T-cell lymphoma (CTCL). Clin Lymphoma 2000;1(Suppl 1):S41-4.
8. Orfanos CE, Zouboulis CC, Almond-Roesler B, et al. Current use and future potential role of retinoids in dermatology. Drugs 1997;53(3):358-88.
9. Peck R, Bollag W. Potentiation of retinoid-induced differentiation of HL-60 and U937 cell lines by cytokines [comment]. Eur J Cancer 1991;27(1):53-7.
10. Bollag W, Holdener EE. Retinoids in cancer prevention and therapy. Ann Oncol 1992;3(7): 513-26.
11. Kligman AM, Fulton Jr JE, Plewig G. Topical vitamin A acid in acne vulgaris. Arch Dermatol 1969;99(4):469-76.
12. Frey JR, Peck R, Bollag W. Antiproliferative activity of retinoids, interferon alpha and their combination in five human transformed cell lines. Cancer Lett 1991;57(3):223-7.
13. Cheng AL, Chuang SE, Su IJ. Factors associated with the therapeutic efficacy of retinoic acids on malignant lymphomas. J Formos Med Assoc 1997;96(7):525-34.
14. Fujimura S, Suzumiya J, Anzai K, et al. Retinoic acids induce growth inhibition and apoptosis in adult T-cell leukemia (ATL) cell lines. Leuk Res 1998;22(7):611-8.
15. Collins SJ. The role of retinoids and retinoic acid receptors in normal hematopoiesis. Leukemia 2002;16(10):1896-905.
16. Sundaresan A, Claypool K, Mehta K, et al. Retinoid-mediated inhibition of cell growth with stimulation of apoptosis in aggressive B-cell lymphomas. Cell Growth Differ 1997;8(10):1071-82.
17. Wang KC, Cheng AL, Chuang SE, et al. Retinoic acid-induced apoptotic pathway in T-cell lymphoma: identification of four groups of genes with differential biological functions. Exp Hematol 2000;28(12):1441-50.
18. Zhang C, Hazarika P, Ni X, et al. Induction of apoptosis by bexarotene in cutaneous T-cell lymphoma cells: relevance to mechanism of therapeutic action. Clin Cancer Res 2002;8(5): 1234-40.
19. Meunier L, Bohjanen K, Voorhees JJ, et al. Retinoic acid upregulates human Langerhans cell antigen presentation and surface expression of HLA-DR and CD11c, a beta 2 integrin critically involved in T-cell activation. J Invest Dermatol 1994;103(6):775-9.
20. Sidell N, Kummer U, Aframian D, et al. Retinoid regulation of interleukin-2 receptors on human T-cells. Cell Immunol 1997;179(2):116-25.
21. Rook AH, Kubin M, Fox FE, et al. The potential therapeutic role of interleukin-12 in cutaneous T-cell lymphoma. Ann N Y Acad Sci 1996;795:310-8.
22. Fox FE, Kubin M, Cassin M, et al. Retinoids synergize with interleukin-2 to augment IFN-gamma and interleukin-12 production by human peripheral blood mononuclear cells. J Interferon Cytokine Res 1999;19(4):407-15.
23. Dummer R, Kohl O, Gillessen J, et al. Peripheral blood mononuclear cells in patients with nonleukemic cutaneous T-cell lymphoma. Reduced proliferation and preferential secretion of a T helper-2-like cytokine pattern on stimulation. Arch Dermatol 1993;129(4):433-6.
24. Pigatto PD, Bersani L, Colotta F, et al. Effect of retinoids on natural killer cell activity. Arch Dermatol Res 1986;278(6):507-9.
25. Gallagher RE. Retinoic acid resistance in acute promyelocytic leukemia. Leukemia 2002;16(10):1940-58.
26. Marks R. Retinoids in cutaneous malignancies. Boston: Blackwell Scientific Publications; 1991.
27. Huang ME, Ye YC, Chen SR, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988;72(2):567-72.
28. Sacchi S, Russo D, Avvisati G, et al. All-trans retinoic acid in hematological malignancies, an update. GER (Gruppo Ematologico Retinoidi). Haematologica 1997;82(1):106-21.
29. Warrell Jr RP, Coonley CJ, Kempin SJ, et al. Isotretinoin in cutaneous T-cell lymphoma. Lancet 1983;2(8350):629.
30. Kessler JF, Meyskens Jr FL, Levine N, et al. Treatment of cutaneous T-cell lymphoma (mycosis fungoides) with 13-cis-retinoic acid. Lancet 1983;1(8338):1345-7.
31. Thomsen K, Molin L, Volden G, et al. 13-cis-retinoic acid effective in mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1984;64(6):563-6.
32. Kessler JF, Jones SE, Levine N, et al. Isotretinoin and cutaneous helper T-cell lymphoma (mycosis fungoides). Arch Dermatol 1987;123(2):201-4.
33. Molin L, Thomsen K, Volden G, et al. Oral retinoids in mycosis fungoides and Sezary syndrome: a comparison of isotretinoin and etretinate. A study from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987;67(3):232-6.
34. Neely SM, Mehlmauer M, Feinstein DI. The effect of isotretinoin in six patients with cutaneous T-cell lymphoma. Arch Intern Med 1987;147(3):529-31.
35. Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol 1991;24(2 Pt 1): 247-52.
36. Thomsen K, Hammar H, Molin L, et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1989;69(6):536-8.
37. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma [erratum appears in J Am Acad Dermatol 1996;35(4):587]. J Am Acad Dermatol 1996;34(6):1022-9.
38. Duvic M, Lemak NA, Redman JR, et al. Combined modality therapy for cutaneous T-cell lymphoma [erratum appears in J Am Acad Dermatol 1996;35(4):587]. J Am Acad Dermatol 1996;34(6):1022-9.
39. Claudy AL, Rouchouse B, Boucheron S, et al. Treatment of cutaneous lymphoma with etretinate. Br J Dermatol 1983;109(1):49-56.
40. Claudy AL, Delomier Y, Hermier C. Treatment of cutaneous T-cell lymphoma with a new aromatic retinoid (Ro 10-9359). Arch Dermatol Res 1982;273(1-2):37-42.
41. Wargon O, Downie D. A case of mycosis fungoides treated with etretinate. Australas J Dermatol 1984;25(2):77-9.
42. Mahrle G, Thiele B. Retinoids in cutaneous T cell lymphomas. Dermatologica 1987;175(Suppl 1): 145-50.
43. Serri F, De Simone C, Venier A, et al. Combination of retinoids and PUVA (Re-PUVA) in the treatment of cutaneous T cell lymphomas. Curr Probl Dermatol 1990;19:252-7.
44. Thestrup-Pedersen K, Hammer R, Kaltoft K, et al. Treatment of mycosis fungoides with recombinant interferon-alpha 2a2 alone and in combination with etretinate. Br J Dermatol 1988;118(6): 811-8.
45. Altomare GF, Capella GL, Pigatto PD, et al. Intramuscular low dose alpha-2B interferon and etretinate for treatment of mycosis fungoides. Int J Dermatol 1993;32(2):138-41.
46. Dreno B, Celerier P, Litoux P. Roferon-A in combination with Tigason in cutaneous T-cell lymphomas. Acta Haematol 1993;89(Suppl 1):28-32.
47. Torii H, Kaneko T, Matsuyama T, et al. Interferon-alpha (INF-alpha) and etretinate in the treatment of mycosis fungoides. J Dermatol 1994;21:767-70.
48. Aviles A, Guzman R, Garcia EL, et al. Biological modifiers (etretinate (changed from etetrinate) and alfa 2a) in the treatment of refractory cutaneous T-cell lymphoma. Cancer Biother Radiopharm 1996;11(1):21-4.
49. Zachariae H, Grunnet E, Thestrup-Pedersen K, et al. Oral retinoid in combination with bleomycin, cyclophosphamide, prednisone and transfer factor in mycosis fungoides. Acta Derm Venereol 1982;62(2):162-4.
50. Ippolito F, Giacalone B. [A case of mycosis fungoides with tumoral manifestations, treated with RO 10-9359 (Tigason)]. Ann Dermatol Venereol 1982;109(1):65-72.
51. Molin L, Thomsen K, Volden G, et al. Retinoids and systemic chemotherapy in cases of advanced mycosis fungoides. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1987;67(2):179-82.
52. Jones G, McLean J, Rosenthal D, et al. Combined treatment with oral etretinate and electron beam therapy in patients with cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome). J Am Acad Dermatol 1992;26(6):960-7.
53. Lim HW, Harris HR. Etretinate as an effective adjunctive therapy for recalcitrant palmar/plantar hyperkeratosis in patients with erythrodermic cutaneous T cell lymphoma undergoing photopheresis. Dermatol Surg 1995;21(7):597-9.
54. Dreno B. Roferon-A (interferon alpha 2a) combined with Tigason (etretinate) for treatment of cutaneous T cell lymphomas. Stem Cells 1993;11(4):269-75.
55. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998;92(10):3578-81.
56. Tousignant J, Raymond GP, Light MJ. Treatment of cutaneous T-cell lymphoma with the arotinoid Ro 13-6298. J Am Acad Dermatol 1987;16(1 Pt 2):167-71.
57. Kontochristopoulos GJ, Exadaktylou D, Hatziolou E, et al. Follicular mucinosis associated with early stage cutaneous T-cell lymphoma: successful treatment with interferon alpha-2b and acitretin. J Dermatolog Treat 2001;12(2):117-21.
58. Bauch B, Barraud-Klenowssek M, Burg G, et al. Eindrucksvolle remission einer mycosis fungoides in tumrostadium unter low-dose interferon-alpha und acitretin nach erfolgloser. [Impressive remission of mycosis fungoides in tumor stage during low-dose interferon-alpha and acitretin after inefficient chemotherapy.] Chemotherapie 1995;70:200-3.
59. Fernandez-Redondo V, Vazquez J, Sanchez-Aguilar D, et al. Sarcoid-like granuloma following prolonged etretinate treatment. Dermatology 1994;188(3):226-7.
60. Molin L, Thomsen K, Volden G, et al. Retinoid dermatitis mimicking progression in mycosis fungoides: a report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol 1985;65(1):69-71.
61. Hurst RE. Bexarotene ligand pharmaceuticals. Curr Opin Investig Drugs 2000;1(4):514-23.
62. Lowe MN, Plosker GL. Bexarotene. Am J Clin Dermatol 2000;1(4):245-50 [discussion 51-2].
63. Heald P. The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clin Lymphoma 2000;1(Suppl 1):S45-9.
64. Duvic M, Martin AG, Kim Y, et al. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol 2001;137(5):581-93.
65. Prince HM, McCormack C, Ryan G. Bexarotene capsules and gel for previously treated patients with cutaneous T-cell lymphoma: results of the Australian patients treated on phase II trials. Aust J Dermatol 2001;42:91-7.
66. Talpur R, Ward S, Apisarnthanarax N, Breuer-Mcham J, Duvic M. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol 2002;47(5):672-84.
67. Duvic M, Hymes K, Heald P, et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001;19(9):2456-71.
68. DiVenuti FM, Foss FM. Phase I dose escalation study of Targretin and ONTAK in hematologic malignancies: upregulation of IL2R expression by low dose Targretin. Presented at the 43rd Annual Meeting of the American Society of Hematology. 2001.
69. Duvic M. Bexarotene and DAB(389)IL-2 (denileukin diftitox, ONTAK) in treatment of cutaneous T-cell lymphomas: algorithms. Clin Lymphoma 2000;1(Suppl 1):S51-5.
70. Apisarnthanarax N, Talpur R, Duvic M. Treatment of cutaneous T cell lymphoma: current status and future directions. Am J Clin Dermatol 2002;3(3):193-215.
71. Sherman SI, Gopal J, Haugen BR, et al. Central hypothyroidism associated with retinoid X receptor-selective ligands. N Engl J Med 1999;340(14):1075-9.
72. Majewski S, Kutner A, Jablonska S. Vitamin D analogs in cutaneous malignancies. Curr Pharm Des 2000;6(7):829-38.
73. French LE, Saurat JH. Treatment of cutaneous T-cell lymphoma by retinoids and calcitriol [comment]. Lancet 1995;346(8971):376.
74. Thomsen K. Cutaneous T-cell lymphoma and calcitriol and isotretinoin treatment [comment]. Lancet 1995;345(8964):1583.
75. Heald P, Mehlmauer M, Martin A. The benefits of topical bexarotene (Targretin) in patients with refractory or persistent early stages CTCL [abstract]. J Invest Dermatol 2000;114:840.
76. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 trial of bexarotene gel for skin-directed treatment of patients with cutaneous T-cell lymphoma [comment]. Arch Dermatol 2002;138(3): 325-32.
77. Breneman D, Duvic M, Martin A, et al. Long-term treatment of patients with early stage cutaneous T-cell lymphoma with bexarotene gel 1%. Presented at the 60th Annual Meeting of the American Academy of Dermatology. New Orleans, February 22-27, 2002.
78. Bassiri-Tehrani S, Ba BA, Cohen DE. Treatment of cutaneous T-cell lymphoma with alitretinoin gel. Int J Dermatol 2002;41(2):104-6.
79. Whaley KL, Cather J, Walker D, et al. Topical retinoids improve stage I cutaneous T-cell lymphoma lesions [abstract]. J Invest Dermatol 1997;108:635.
80. Wyss M, Dummer R, Dommann SN, et al. Lymphomatoid papulosis-treatment with recombinant interferon alfa-2a and etretinate. Dermatology 1995;190(4):288-91.
81. Chow JM, Cheng AL, Su IJ, et al. 13-cis-retinoic acid induces cellular differentiation and durable remission in refractory cutaneous ki-I lymphoma. Cancer 1991;67:2490-4.
82. Chou WC, Su IJ, Tien HF, et al. Clinicopathologic, cytogenetic, and molecular studies of 13 Chinese Patients with Ki-1 anaplastic large cell lymphoma. Special emphasis on the tumor response to 13-cis retinoic acid. Cancer 1996;78(8):1805-12.
83. Ong C, Sullivan J, Hertzberg M, et al. Stage IV CD30 + anaplastic large cell lymphoma: response to acitretin and interferon-alpha. Australas J Dermatol 2002;43(3):207-10.
84. Krathen R, Wards S, Duvic M. Bexarotene is a new treatment option for lymphomatoid papulous. Dermatology 2003;206:142-7.
85. Foss FM, Kuzel TM. Experimental therapies in the treatment of cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995;9(5):1127-37.
86. Miller VA, Benedetti FM, Rigas JR, et al. Initial clinical trial of a selective retinoid X receptor ligand. LGD1069. J Clin Oncol 1997;15(2):790-5.